Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine Biosciences. Osavampator, formerly known as NBI ...

Neurocrine Biosciences amended its Takeda agreement, gaining exclusive global rights to osavampator for major depressive disorder. Phase 2 data for osavampator showed significant MADRS score ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder. The San Diego ...

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine ...

Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX), a neuroscience-focused, biopharmaceutical company, on Tuesday announced the initiation of a Phase 3 registrational study to evaluate the efficacy ...

On Monday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) amended its agreement with Takeda Pharmaceutical Co Ltd (NYSE: TAK ) to develop and commercialize osavampator (NBI-1065845/TAK-653).